Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
grade B 64.58 -1.22% -0.80
QURE closed down 1.22 percent on Thursday, December 5, 2019, on 1.43 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical QURE trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Pocket Pivot Bullish Swing Setup -1.22%
Calm After Storm Range Contraction -1.22%
Stochastic Reached Overbought Strength -1.22%
Upper Bollinger Band Walk Strength -1.22%

Older signals for QURE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biopharmaceutical Biology Diseases Gene Therapy Genetics Parkinson's Disease Applied Genetics Gene Delivery Treatment Of Hemophilia Adeno Associated Virus AAV Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B

Is QURE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicator Value
52 Week High 82.49
52 Week Low 24.07
Average Volume 523,518
200-Day Moving Average 57.95
50-Day Moving Average 48.82
20-Day Moving Average 55.46
10-Day Moving Average 57.42
Average True Range 3.06
ADX 35.34
+DI 41.39
-DI 10.48
Chandelier Exit (Long, 3 ATRs ) 59.30
Chandelier Exit (Short, 3 ATRs ) 58.77
Upper Bollinger Band 63.59
Lower Bollinger Band 47.34
Percent B (%b) 1.06
BandWidth 29.29
MACD Line 3.49
MACD Signal Line 2.50
MACD Histogram 0.9918
Fundamentals Value
Market Cap 1.65 Billion
Num Shares 25.6 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -22.90
Price-to-Sales 16.30
Price-to-Book 14.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 71.18
Resistance 3 (R3) 71.74 70.11 70.08
Resistance 2 (R2) 70.11 68.43 69.83 69.71
Resistance 1 (R1) 67.34 67.39 66.53 66.78 69.35
Pivot Point 65.71 65.71 65.30 65.43 65.71
Support 1 (S1) 62.94 64.03 62.13 62.38 59.81
Support 2 (S2) 61.31 62.99 61.03 59.45
Support 3 (S3) 58.54 61.31 59.08
Support 4 (S4) 57.98